TERN-701 is under clinical development by Terns Pharmaceuticals and currently in Phase I for Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia). According to GlobalData, Phase I drugs for Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) have a 69% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how TERN-701’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
TERN-701 overview
TERN-701 is under development for the treatment of chronic myelocytic leukemia. The drug candidate is administered through oral route as a tablet. It acts by targeting BCR-ABL tyrosine kinase.
Terns Pharmaceuticals overview
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company that develops a portfolio of small-molecule product candidates to address serious diseases such as oncology and obesity. The company’s pipeline products include TERN- 701 which treats chronic myelogenous leukemia (CML); TERN-601, TERN-501 Combination and TERN-800 Series treats obesity. Terns Pharmaceuticals pipeline features three clinical-stage programs: an allosteric BCR-ABL inhibitor, a small-molecule GLP-1 receptor agonist, and a THR-ß agonist. The company operates in China, Hong Kong and the US. Terns Pharmaceuticals is headquartered in Foster City, California, the US.
For a complete picture of TERN-701’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
